Leflunomide and its analogue X920715 synergize with cyclosporin A in preventing early graft failure and delaying graft rejection of xenogeneic islets in nonobese diabetic mice.
Gysemans
C
C
Department of Experimental Medicine and Endocrinology (LEGENDO), Catholic University of Leuven, Campus Gaithuisberg, Leuven, Belgium.
Waer
M
M
Laureys
J
J
Bouillon
R
R
Mathieu
C
C
D000480:Alkynes; D000818:Animals; D016572:Cyclosporine / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D004357:Drug Synergism; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D007555:Isoxazoles / Q000627:therapeutic use*; D000077339:Leflunomide; D051379:Mice; D016688:Mice, Inbred NOD; D009570:Nitriles / Q000627:therapeutic use*; D051381:Rats; D014183:Transplantation, Heterologous / Q000276:immunology*
D000480:Alkynes; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; D016572:Cyclosporine; D000077339:Leflunomide